Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

Published:2019-01 Issue:1 Volume:6 Page:e12-e19
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Shi Yuankai,Su Hang,Song Yongping,Jiang Wenqi,Sun Xiuhua,Qian Wenbin,Zhang Wei,Gao Yuhuan,Jin Zhengming,Zhou Jianfeng,Jin Chuan,Zou Liqun,Qiu Lugui,Li Wei,Yang Jianmin,Hou Ming,Zeng Shan,Zhang Qingyuan,Hu Jianda,Zhou Hui,Xiong Yan,Liu Peng

Funder

National New Drug Innovation Programme

National Key Scientific Programme Precision Medicine Research Fund of China

Publisher

Elsevier BV

Subject

Hematology

Reference16 articles.

1. The biology of Hodgkin's lymphoma;Küppers;Nat Rev Cancer,2009

2. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management;Ansell;Am J Hematol,2018

3. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure;Armand;J Clin Oncol,2016

4. Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma;Merryman;Blood Adv,2017

5. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma;Green;Blood,2010

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrating Novel Agents Into the Clinical Management of Classic Hodgkin Lymphoma;JCO Oncology Practice;2024-09-12

2. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy;Current Treatment Options in Oncology;2024-09-11

3. Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-09-06

4. Cost-effectiveness analysis of first-line sintilimab plus chemotherapy vs. chemotherapy alone for unresectable advanced or metastatic gastric or gastroesophageal junction cancer in China;Frontiers in Pharmacology;2024-09-04

5. Etoposide, cisplatin, and sintilimab combined with anlotinib in successful treatment of adrenocortical carcinoma with lung metastasis: a case report;Frontiers in Oncology;2024-08-16